Saliva molecular inflammatory profiling in female migraine patients responsive to adjunctive cervical non-invasive vagus nerve stimulation: the MOXY Study

Table 3 Functional state (body weight, sleep, mood, quality of life) and saliva concentrations of oxytocin and IL-1ß at baseline

Patient no	BMI kg/m²	Migraine Type	MIDAS score/grade	BDI score	PSQI score	EQ-5D-5L	Oxytocin saliva pg/ml	IL-1ß saliva pg/ml
1	22	CM+	93/IV	25	8	12	61.6	215
2	19	EM+	13/III	2	2	6	27.5	195
3	23	EM−	92/IV	23	10	15	24.1	1000
4	27	EM−	39/IV	20	10	5	29.6	822
5	28	CM+	73/IV	44	13	18	105.3	334
6	20	EM−	40/IV	12	10	8	20.6	194
7	24	EM+	51/IV	7	9	9	16.3	168
8	22	EM−	2/I	9	10	7	41	261
9	28	EM+	47/IV	6	13	7	120.7	1000
10	27	EM+	16/III	12	7	11	16.9	272
11	24	EM+	106/IV	10	19	14	44.2	730
12	19	EM−	17/III	0	4	8	22.7	262

BDI Becks depression inventory, BMI body mass index, CM chronic migraine, EM episodic migraine, EQ-5D-5L EuroQol five-dimensional five level scale, f female, MIDAS Migraine Disability Assessment, PSQI Pittsburgh Sleep Quality Index